FRAKIDEX

• in the aftermath of ophthalmological surgery,.

• infections due to framycetin-sensitive germs with inflammatory component.

o In patients with a high degree of ophthalmosis, the ophthalmosis of the ophthalmosis is a serious problem.

o Aerobic strain aerobic strain aerobic strain aerobic strain aerobic strain aerobic strain aerobic strain aerobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic agent arobic acid arobic acid arobic agent.

• Possible local transient irritation: pruritus and swelling of the eyelids and conjunctival erythema.

• In prolonged use: risk of cortico-induced eye hypertension, d-opacification of the lens, superficial keratitis due to the presence of corticosteroid.

• In case of corneal or scleral ulceration, corticosteroids may delay healing and promote overinfection.

• - Not known: blurred vision Endocrine disorders:

• Not known: Cushing syndrome, adrenal inhibition Reporting suspected adverse reactions Reporting suspected adverse reactions after authorization of the drug is important.

It allows for continuous monitoring of the benefit/risk ratio of the drug.

Health care professionals report any suspected adverse effects via the national reporting system: National Drug and Health Products Safety Agency (NSMA) and Network of Regional Pharmacovigilance Centres.

• Website: https-social.uv.://seu.int/.htm.